Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

IF 1.5 Q3 PERIPHERAL VASCULAR DISEASE Current Hypertension Reviews Pub Date : 2021-01-01 DOI:10.2174/1573402116666200817113125
Godela M Brosnahan, Zhiying You, Wei Wang, Berenice Y Gitomer, Michel Chonchol
{"title":"Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.","authors":"Godela M Brosnahan,&nbsp;Zhiying You,&nbsp;Wei Wang,&nbsp;Berenice Y Gitomer,&nbsp;Michel Chonchol","doi":"10.2174/1573402116666200817113125","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Epidemiological studies have suggested that elevated serum uric acid may contribute to the progression of chronic kidney disease. However, no large prospective study has examined whether hyperuricemia is an independent risk factor for the progression of autosomal dominant polycystic kidney disease (ADPKD).</p><p><strong>Methods: </strong>We measured uric acid in stored serum samples from the 2-year study visit of 671 participants from the HALT PKD multicenter trials. Participants were categorized according to uric acid tertiles. For Study A (participants aged 15-49 years with preserved kidney function, n=350), we used linear mixed effects models to examine the association between uric acid and repeated measures of height-adjusted total kidney volume (htTKV), the primary outcome for Study A. For Study B (participants aged 18-64 with decreased kidney function, n=321), we used Cox proportional hazards models to assess the hazard for the combined endpoint of 50% loss in estimated glomerular filtration rate (eGFR), end-stage kidney disease (ESKD), or death, the primary outcome for Study B. To assess the association of uric acid with the slope of eGFR decline (secondary outcome of HALT A and B), we used linear mixed effects models for the combined population of Study A and B.</p><p><strong>Results: </strong>In the unadjusted model, the annual change in htTKV was 2.7% higher in the highest uric acid tertile compared to the lowest (p<0.001), but this difference became insignificant after adjustment for gender. Men had faster TKV growth than women (p<0.001). There was no difference in eGFR decline between the 3 uric acid tertiles. Hazard ratios for the clinical endpoint were 2.9 (95% confidence interval, 1.9-4.4) and 1.8 (1.1-2.8) respectively in the high and medium uric acid groups in unadjusted and partially adjusted models (p<0.001), but the significance was lost after adjustment for baseline eGFR. Results were similar when uric acid was examined as a continuous variable.</p><p><strong>Conclusion: </strong>Elevated serum uric acid is not an independent risk factor for disease progression in ADPKD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887140/pdf/nihms-1629002.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hypertension Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573402116666200817113125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Epidemiological studies have suggested that elevated serum uric acid may contribute to the progression of chronic kidney disease. However, no large prospective study has examined whether hyperuricemia is an independent risk factor for the progression of autosomal dominant polycystic kidney disease (ADPKD).

Methods: We measured uric acid in stored serum samples from the 2-year study visit of 671 participants from the HALT PKD multicenter trials. Participants were categorized according to uric acid tertiles. For Study A (participants aged 15-49 years with preserved kidney function, n=350), we used linear mixed effects models to examine the association between uric acid and repeated measures of height-adjusted total kidney volume (htTKV), the primary outcome for Study A. For Study B (participants aged 18-64 with decreased kidney function, n=321), we used Cox proportional hazards models to assess the hazard for the combined endpoint of 50% loss in estimated glomerular filtration rate (eGFR), end-stage kidney disease (ESKD), or death, the primary outcome for Study B. To assess the association of uric acid with the slope of eGFR decline (secondary outcome of HALT A and B), we used linear mixed effects models for the combined population of Study A and B.

Results: In the unadjusted model, the annual change in htTKV was 2.7% higher in the highest uric acid tertile compared to the lowest (p<0.001), but this difference became insignificant after adjustment for gender. Men had faster TKV growth than women (p<0.001). There was no difference in eGFR decline between the 3 uric acid tertiles. Hazard ratios for the clinical endpoint were 2.9 (95% confidence interval, 1.9-4.4) and 1.8 (1.1-2.8) respectively in the high and medium uric acid groups in unadjusted and partially adjusted models (p<0.001), but the significance was lost after adjustment for baseline eGFR. Results were similar when uric acid was examined as a continuous variable.

Conclusion: Elevated serum uric acid is not an independent risk factor for disease progression in ADPKD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
血清尿酸与常染色体显性多囊肾病的进展:来自HALT PKD试验的结果
背景:流行病学研究表明,血清尿酸升高可能与慢性肾脏疾病的进展有关。然而,尚无大型前瞻性研究检验高尿酸血症是否是常染色体显性多囊肾病(ADPKD)进展的独立危险因素。方法:我们测量了来自HALT PKD多中心试验的671名参与者为期2年的研究访问中储存的血清样本中的尿酸。参与者根据尿酸等级进行分类。对于研究A(年龄15-49岁,肾功能保存,n=350),我们使用线性混合效应模型来检验尿酸与重复测量身高调整后的总肾体积(htTKV)之间的关系,这是研究A的主要结局。对于研究B(年龄18-64岁,肾功能下降,n=321),我们使用Cox比例风险模型来评估肾小球滤过率(eGFR)估计损失50%的联合终点的风险。为了评估尿酸与eGFR下降斜率(HALT A和B的次要结局)之间的关系,我们对研究A和B的合并人群使用了线性混合效应模型。结果:在未经调整的模型中,尿酸最高的人群的htTKV年变化比最低的人群高2.7% (p)。血清尿酸升高不是ADPKD疾病进展的独立危险因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Hypertension Reviews
Current Hypertension Reviews PERIPHERAL VASCULAR DISEASE-
CiteScore
4.80
自引率
0.00%
发文量
26
期刊介绍: Current Hypertension Reviews publishes frontier reviews/ mini-reviews, original research articles and guest edited thematic issues on all the latest advances on hypertension and its related areas e.g. nephrology, clinical care, and therapy. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all clinicians and researchers in the field of hypertension.
期刊最新文献
Association of Angiotensin Converting Enzyme Phenotypes and Polymorphisms with Clinical Outcomes in SARS-CoV2 Patients with Hypertension in an Urban Emergency Department. Investigating the Effect of COVID-19 on Pregnancy-Induced Hypertension (HTN): A Case-Control Study. Polyphenol-Mediated Modulation of Non-Coding RNAs: A New Therapeutic Approach for Hypertension - A Review. Exploring the Challenges of Recruiting Older People for a Randomised Trial Assessing the Feasibility of Treating White Coat Hypertension in the UK General Practices: A Mixed-methods study. The New Editor-In-Chief Note.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1